Kevin Horgan

Kevin Horgan, M.D. is a board-certified internist and gastroenterologist with extensive experience in therapeutics and diagnostics development. Dr. Horgan received his medical degree from University College, Cork, Ireland and completed training in internal medicine at the Queen Elizabeth Hospital, Birmingham, United Kingdom and at Johns Hopkins University Hospital, Baltimore, MD. Following an immunology research fellowship at the National Cancer Institute in Bethesda, MD, and a gastroenterology fellowship at the University of California at Los Angeles, he served on the UCLA faculty for four years. Dr. Horgan joined Merck in 1997 and led the development of the first neurokinin-1 receptor antagonist, EMEND, to be approved for the prevention of chemotherapy-induced nausea and vomiting in 2003. From 2006 to 2008, he was Vice President of Clinical Immunology at Centocor Ortho Biotech Inc. In 2008, Dr. Horgan joined General Electric Healthcare as Head of Internal Medicine Research and Development in molecular diagnostics with a focus on oncology and neuroscience, where he designed the development program for GE’s amyloid PET imaging agent flutemetamol.